Oxymatrine inhibits collagen synthesis in keloid fibroblasts via inhibition of transforming growth factor-β1/Smad signaling pathway

International Journal of Dermatology

Volumn 51, Issue 4, 2012, Pages 463-472

  Fan, Dong Liang ^a,b   Zhao, Wei Jin ^b   Wang, Yu Xin ^a   Han, Si Yuan ^a   Guo, Shu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b General Hospital of Benxi Steel and Iron Company   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; OXYMATRINE; SMAD PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INHIBITION KINETICS; KELOID; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; ALKALOIDS; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; FEMALE; FIBROBLASTS; HUMANS; KELOID; MALE; PHOSPHORYLATION; PROTEIN TRANSPORT; QUINOLIZINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84863392473     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05234.x     Document Type: Article

References (49)

1. Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg 2005; 54: 676-680.
2. Butler PD, Longaker MT, Yang GP, et al. Current progress in keloid research and treatment. J Am Coll Surg 2008; 206: 731-741.
3. Ogawa R, Yoshitatsu S, Yoshida K, et al. Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis. Plast Reconstr Surg 2009; 124: 1196-1201.
4. Tan KT, Shah N, Pritchard SA, et al. The influence of surgical excision margins on keloid prognosis. Ann Plast Surg 2010; 64: 55-58.
5. Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil 2010; 89: 153-155.
6. Wang XQ, Liu YK, Qing C, et al. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids. Ann Plast Surg 2009; 63: 688-692.
7. Stahl S, Barnea Y, Weiss J, et al. Treatment of earlobe keloids by extralesional excision combined with preoperative and postoperative "sandwich" radiotherapy. Plast Reconstr Surg 2010; 125: 135-141.
8. Verrecchia F, Mauviel A. Transforming growth factor-β and fibrosis. World J Gastroenterol 2007; 13: 3056-3065.
9. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-176.
10. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
11. Moustakas A, Heldin CH. The regulation of TGF-beta signal transduction. Development 2009; 136: 3699-3714.
12. Lin HY, Moustakas A. TGF-beta receptors: structure and function. Cell Mol Biol 1994; 40: 337-349.
13. Massague J. TGF-beta signaling: receptors, transducers, and Mad proteins. Cell 1996; 85: 947-950.
14. Owens P, Han G, Li AG, et al. The role of Smads in skin development. J Invest Dermatol 2008; 128: 783-790.
15. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009; 19: 8-20.
16. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-Wbroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006; 208: 336-343.
17. Gao Z, Wang Z, Shi Y, et al. Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. Plast Reconstr Surg 2006; 118: 1328-1337.
18. Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by TGF-beta. Exp Cell Res 2000; 258: 374-383.
19. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118: 211-215.
20. Inagaki Y, Mamura M, Kanamaru Y, et al. Consecutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 2001; 187: 117-123.
21. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964-1978.
22. Liu J, Liu Y, Klaassen CD. The effect of Chinese hepatoprotective medicines on experimental liver injury in mice. J Ethnopharmacol 1994; 42: 183-191.
23. Liu J, Manheimer E, Tsutani K, et al. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003; 98: 538-544.
24. Song G, Luo Q, Qin J, et al. Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B Biointerfaces 2006; 48: 1-5.
25. Dong Y, Xi H, Yu Y, et al. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine. J Gastroenterol Hepatol 2002; 17: 1299-1306.
26. Yang W, Zeng M, Fan Z, et al. Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis (in Chinese, with English abstract). Zhonghua Ganzangbing Zazhi 2002; 10: 193-196.
27. Shi GF, Li Q. Effects of oxymatrine on experimental hepatic fibrosis and its mechanism in vivo. World J Gastroenterol 2005; 11: 268-271.
28. Li S, Yang L, Li J, et al. Immunomodulatory effect of oxymatrine on induced CCl4-hepatic fibrosis in rats. Chin Med J 2004; 117: 1856-1858.
29. Wu XL, Zeng WZ, Jiang MD, et al. Effect of Oxymatrine on the TGF-beta/Smad signaling pathway in rats with CCl4-induced hepatic fibrosis. World J Gastroenterol 2008; 14: 2100-2105.
30. Chen C, Jin Y. Effects of oxymatrine on expression of nuclear factor κB in kidneys of rats with adriamycin-induced chronic renal fibrosis (in Chinese, with English abstract). Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 345-348.
31. Chen XH, Sun RS, Hu JM, et al. Attenuation of bleomycin-induced lung fibrosis by oxymatrine is associated with regulation of fibroblast proliferation and collagen production in primary culture. Basic Clin Pharmacol Toxicol 2008; 103: 278-286.
32. Wu CS, Piao XX, Piao DM. Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-alpha. World J Gastroenterol 2005; 11: 122-126.
33. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
34. Jagadeesan J, Bayat A. Transforming growth factor beta (TGF-beta) and keloid disease. Int J Surg 2007; 5: 278-285.
35. Smith P, Mosiello G, Deluca L, et al. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 1999; 82: 319-323.
36. Chin GS, Liu W, Peled Z, et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001; 108: 423-429.
37. Schmid P, Itin P, Cherry G, et al. Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 1998; 152: 485-493.
38. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353-5362.
39. Wang Z, Gao Z, Shi Y, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg 2007; 60: 1193-1199.
40. Zhang GY, Yi CG, Li X, et al. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. Br J Dermatol 2009; 160: 762-770.
41. Phan TT, Lim IJ, Chan SY, et al. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma 2004; 57: 1032-1037.
42. Liang TJ, Yuan JH, Tan YR, et al. Effect of ursodeoxycholic acid on TGF beta1/Smad signaling pathway in rat hepatic stellate cells. Chin Med J 2009; 122: 1209-1213.
43. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature 2003; 425: 577-584.
44. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFb-inducible transcriptional responses. Genes Dev 1997; 11: 3157-3167.
45. Macias SM, Abdollah S, Hoodless PA, et al. MADR2 is a substrate of the TGFβ receptor and phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87: 1215-1224.
46. Hoodless PA, Haerry T, Abdollah S, et al. MADR1 a MAD-related protein that functions in BMP2 signalling pathways. Cell 1996; 85: 489-500.
47. Nicolas FJ, Hill CS. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003; 22: 3698-3711.
48. Wilson PA, Lagna G, Suzuki A. Concentration-dependent patterning of the Xenopus ectoderm by BMP4 and its signal transducer Smad1. Development 1997; 124: 3177-3184.
49. Wharton SJ, Basu SP, Ashe HL. Smad affinity can direct distinct readouts of the embryonic extracellular Dpp gradient in Drosophila. Curr Biol 2004; 14: 1550-1558.